SLC5A2 and diabetes mellitus: There was a lack of data on the use of treatment agents, such as renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors, which are frequently used in patients with type 2 DKD, as well as other important clinical prognostic factors such as the duration of diabetes mellitus, microscopic hematuria and hemoglobin A1c.